Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO6927005 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
RO6927005 + gemcitabine + nab-paclitaxel is a combination therapy studied in Phase 1 for patients with mesothelin-positive metastatic and/or locally advanced malignant solid tumors, especially pancreatic ductal adenocarcinoma and mesothelioma. RO6927005 (previously known as LMB-100) is a recombinant immunotoxin targeting mesothelin, a cell-surface protein overexpressed in several cancers. Gemcitabine is a nucleoside analog used as an antimetabolite chemotherapeutic. Nab-paclitaxel is nanoparticle albumin-bound paclitaxel, a microtubule inhibitor chemotherapeutic[2][4]. The combination leverages targeted immunotoxin-mediated cytotoxicity (mesothelin), DNA synthesis inhibition (gemcitabine), and anti-mitotic activity (nab-paclitaxel) to enhance anti-tumor effects.
- Other names
- LMB-100 + gemcitabine + nab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))EEF2 (Eukaryotic elongation factor 2)Mesothelin
Beyond the preview
Go deeper on RO6927005 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO6927005 + gemcitabine + nab-paclitaxel.